|
|
 |
|
Viewing report
|
|
|
|
The Antivirals Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Business Insights, Jan 2005
'The Antivirals Market Outlook: Market Analysis of Future Growth and Leading Players by Sector' provides an analysis of changing market conditions and strategic future outlook, an unrivalled source of pharmaceutical intelligence on the Antivirals market.
Refresh your antivirals strategy with new analysis
'The Antivirals Market Outlook: Market analysis of future growth and leading players by sector', analyzes the market development in the US and the five major European markets. The major therapy areas covered in this report are: HIV, hepatitis, herpes, influenza, RSV and HPV. For each market therapy area there is a country-by-country analysis, a review of leading companies and an analysis of key brands allowing you to assess the best pipeline areas to invest in. Identify unmet needs and growth opportunities in each market by reviewing pipeline drugs with the most potential for profit for your company.
Antivirals factfile - know your market
This report provides:
- A breakdown of the antivirals market by key therapy areas, brands and companies, 2002-2003, as well as compound annual growth rates (CAGR) 1999-2003.
- Identification of the key antivirals in development, along with other drug types, used this information to utilise future opporunities and eliminate your weakness in your future strategies.
- An examination of small antiviral markets (influenza, RSV, HPV) which may grow to be more important in the future.
- A breakdown of each therapy area by drug type, viral target, brand and company, 2002-2003.
- An assessment of the unmet needs in each therapy area, highlighting potential growth opportunities. An analysis of the leading companies' strategies within the antiviral market, such as GlaxoSmithKline, BMs and Abbott.
Key findings of this new report
- Following the emergence of new viral diseases, (SARS, Avian Flu and West Nile Virus) in recent years, several companies have begun research into developing antiviral treatments and vaccines to combat these viruses.
- In the HIV market, the entry inhibitor class has just one currently market drug, Fuzeon, but a third of pipeline drugs are in this area, with particular interest in the CCR5 agonists.
- A number of antiviral markets will suffer due to the greater focus on development of prophylactic vaccines, including herpes, influenza, RSV and HPV.
- Growth opportunities exist in the hepatitis B market for more efficacious treatments that are also slower to induce resistance.
- HBV therapy is expected to involve treatment with combinations of antivirals in the future, mirroring HAART in HIV therapy.
- The herpes antiviral market is forecast to show limited growth up to 2010, due to generic competition, poor presentation rates and a lack of innovative product launches.
- There are several growth drivers that are common to all antiviral markets, including the emergence of drug resistance, increasing disease knowledge, limited generic competition and the reduced cost of R&D through genomics
Actionable strategies to drive your profits forward
- Save valuable time and budget on antivirals market research with this report's expert analysis of all major aniviral drugs, using gold standard IMS Health data.
- Increase your market share by identifying where the major growth opportunities lie and exploiting the unmet needs in each antiviral market.
- Evaluate the potential for line extensions of brands into additional viral fields, as demonstrated by GSK's lamivudine strategy.
- Assess the importance of prophylactic vaccines and antiviral treatments in various therapy areas, as there is a greater potential for prophylactic therapies than antiviral treatments in the RSV market.
- Identify the most commercially attractive sectors with potential for rapid growth and successive novel product entries and improve your product pipeline with a succinct compilation and analysis of all the major market data.
Reviews
'The report represents an excellent source for common background regarding key drivers of parallel trade. Moreover it's very helpful to predict the future impact of parallel trade on our market thus more detailed forecasts are possible. Altogether it provides me with all essential information on parallel trade which are necessary for future business planning...'
Health Economics Manager
Bristol-Myers Squibb
'The outlook report offered me a very clear and concise picture of how the market is going to develop over the next years in all its aspects, from epidemiological factors and possible treatments to who are the players in the market. We regularly use this information to help us gain a 360 degree vision of the market for the next
5 years, in order to develop our strategic plans...'
Group Product Manager
Bayer
|
|
|
|
